Hiromitsu Kumada

Summary

Affiliation: Toranomon Hospital
Country: Japan

Publications

  1. pmc A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma
    Takuji Okusaka
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Invest New Drugs 30:2015-25. 2012
  2. doi request reprint Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
    Hiromitsu Kumada
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Hepatol 56:78-84. 2012
  3. ncbi request reprint Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 79:1686-95. 2007
  4. ncbi request reprint Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Toranomon, Minato ku, Tokyo, Japan
    J Med Virol 79:1485-90. 2007
  5. ncbi request reprint Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 48:253-8. 2009
  6. ncbi request reprint A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 51:603-9. 2006
  7. ncbi request reprint Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 80:1354-62. 2008
  8. ncbi request reprint Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 49:739-44. 2009
  9. doi request reprint A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 81:452-8. 2009
  10. ncbi request reprint Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 50:361-8. 2007

Detail Information

Publications64

  1. pmc A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma
    Takuji Okusaka
    Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, 5 1 1 Tsukiji, Chuo Ku, Tokyo, 104 0045, Japan
    Invest New Drugs 30:2015-25. 2012
    ..We conducted a multicenter phase II trial in patients with HCC to evaluate the efficacy and safety of SM-11355, using a Zinostatin stimalamer suspension in iodized oil as a reference...
  2. doi request reprint Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan
    Hiromitsu Kumada
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Hepatol 56:78-84. 2012
    ..To evaluate the efficacy and safety of telaprevir in combination with peginterferon-α2b (PEG-IFN) and ribavirin (RBV) in patients with chronic hepatitis C...
  3. ncbi request reprint Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 79:1686-95. 2007
    ..This study identified predictors of efficacy of PEG-IFN-RBV therapy based on viral kinetics in Japanese patients infected with HCV genotype 1b...
  4. ncbi request reprint Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Toranomon, Minato ku, Tokyo, Japan
    J Med Virol 79:1485-90. 2007
    ..026). The relative risk of HCC development in patients with BR was 0.36 compared with patients without BR. The attainment of BR during IFN therapy is effective in reducing hepatocarcinogenesis for patients with chronic HCV infection...
  5. ncbi request reprint Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 48:253-8. 2009
    ..The aim of this study was to evaluate the efficacy of combination therapy of peginterferon and ribavirin in patients infected with hepatitis C virus (HCV) genotype 1b and low virus load...
  6. ncbi request reprint A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 51:603-9. 2006
    ....
  7. ncbi request reprint Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 80:1354-62. 2008
    ..The results highlight the importance of eradication of mutant type virus of aa 70 for reducing the risk of hepatocarcinogenesis...
  8. ncbi request reprint Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 49:739-44. 2009
    ..73; 95% CI 1.77-4.20; P < 0.001), the patient had pre-diabetes (hazard ratio 2.19; 95% CI 1.43-3.37; P < 0.001), and age was >or=50 years (hazard ratio 2.10; 95% CI 1.38-3.18; P < 0.001)...
  9. doi request reprint A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 81:452-8. 2009
    ..Substitution of aa 70 and 91 is also a useful pretreatment predictor of response to 72-week PEG-IFN/RBV...
  10. ncbi request reprint Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 50:361-8. 2007
    ..To evaluate power of amino acid polymorphisms in core protein of hepatitis C virus (HCV) for predicting sustained virological response (SVR) to pegylated interferon (Peg-IFN)/ribavirin, when they were combined with virological response...
  11. ncbi request reprint Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol l
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Hepatol 46:403-10. 2007
    ..Here, we determined the predictive factors of sustained virological response (SVR) and early virologic response (EVR) to this treatment...
  12. doi request reprint Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:385-93. 2008
    ..The long-term efficacy of adefovir dipivoxil in combination with lamivudine to chronic hepatitis B virus (HBV) infection is still unclear...
  13. doi request reprint Necessities of interferon therapy in elderly patients with chronic hepatitis C
    Kenji Ikeda
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Med 122:479-86. 2009
    ..The significance of antiviral therapy for elderly patients with chronic hepatitis C virus (HCV) infection has not been elucidated...
  14. ncbi request reprint Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C
    Yasuji Arase
    Department of Gastroenterology, and Hepatic Research Unit, Toranomon Hospital, Toranomon, Tokyo, Japan
    Intervirology 50:16-23. 2007
    ..The purpose of this study was to elucidate the long-term outcome after interferon (IFN) therapy in chronic hepatitis C elderly patients...
  15. doi request reprint Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients
    Hiromi Saneto
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol 43:975-81. 2008
    ..The aim of this retrospective study was to determine the incidence and characteristics of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV) antibody-positive elderly patients with chronic hepatitis without cirrhosis...
  16. doi request reprint Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 82:41-8. 2010
    ....
  17. doi request reprint Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 82:575-82. 2010
    ....
  18. ncbi request reprint Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 80:1363-9. 2008
    ....
  19. ncbi request reprint Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Minato, Tokyo, Japan
    J Gastroenterol Hepatol 20:426-32. 2005
    ..The purpose of the present paper was to identify factors that could influence the rapid progression of liver disease to hepatic failure, and assess the effects of lamivudine on serious disease...
  20. doi request reprint HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy
    Tetsuya Hosaka
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Liver Int 30:1461-70. 2010
    ....
  21. ncbi request reprint Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients
    Fumitaka Suzuki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol Hepatol 25:892-8. 2010
    ..To assess the efficacy of switching Japanese chronic hepatitis B patients from lamivudine monotherapy to entecavir 0.5 mg/day...
  22. ncbi request reprint Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 48:372-80. 2005
    ..Non-virological responders (NVRs, namely ultimate resistant cases) who do not achieve HCV-RNA negativity during treatment are also encountered. We investigated the pretreatment virological features of NVRs...
  23. doi request reprint Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 55:417-25. 2012
    ....
  24. ncbi request reprint Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 46:1155-60. 2007
    ..The aim of this study was to evaluate whether or not combination therapy of pegylated interferon (IFN) and ribavirin for chronic hepatitis (CH) C patients enhances the serum level of KL-6, a sensitive marker for interstitial pneumonia...
  25. doi request reprint An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads
    Hitomi Sezaki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 52:43-8. 2009
    ..Response to pegylated (PEG) interferon (IFN) and ribavirin is achieved only in 40-50% of patients infected with hepatitis C virus (HCV) of genotype 1 in high viral loads, which needs to be improved...
  26. ncbi request reprint Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 79:1286-92. 2007
    ..002). Our results suggest that (1) IFN and LMV are the similar effect on response, (2) IFN therapy is more effective for younger patients...
  27. ncbi request reprint Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis
    Takashi Someya
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Gastroenterol 41:1206-13. 2006
    ..Hepatocellular carcinoma (HCC) caused by hepatitis B virus (HBV) often recurs after surgical or medical treatment...
  28. ncbi request reprint Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:83-90. 2006
    ....
  29. doi request reprint Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Yoshiyuki Suzuki
    Department of Hepatology, Toranomon Hospital, Takatsu ku, Kawasaki City, Japan
    J Gastroenterol Hepatol 24:429-35. 2009
    ..However, hepatitis B virus (HBV) mutants resistant to lamivudine emerge frequently accompanied by breakthrough hepatitis...
  30. ncbi request reprint Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Toranomon 2 2 2, Minato ku, Tokyo 105 8470, Japan
    Intervirology 49:82-90. 2006
    ..The anticarcinogenic capacity of interferon (IFN) was assessed in a cohort of Japanese patients with chronic hepatitis C en masse...
  31. ncbi request reprint High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol 39:155-61. 2004
    ....
  32. doi request reprint Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up
    Hiromi Yatsuji
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Hepatol 48:923-31. 2008
    ..We studied the long-term efficacy (median follow-up of 28 months) of adefovir (ADV) in combination with lamivudine (LAM) in 132 LAM-resistant Japanese patients with chronic genotype C-dominant hepatitis B virus (HBV) infection...
  33. ncbi request reprint Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Med Virol 75:27-34. 2005
    ..919. The results suggest that early monitoring of viral kinetics is a useful measure to predict virological response, and might facilitate development of rational and effective therapeutic strategies...
  34. doi request reprint Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:1-6. 2008
    ..The aim of this study was to elucidate efficacy after dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C...
  35. ncbi request reprint Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 46:1357-64. 2007
    ..In multicourse IFN therapy to nondouble wild-type, we emphasize the importance of reducing the risk of hepatocarcinogenesis by mean ALT during an IFN-free period below 1.5 times the upper limit of normal...
  36. doi request reprint Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    Am J Med 123:951-956.e1. 2010
    ..This retrospective cohort study assessed the impact of diabetes mellitus on hepatocarcinogenesis and determined the predictors of hepatocarcinogenesis in noncirrhotic, interferon-treated patients with hepatitis C virus infection...
  37. doi request reprint Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 52:421-9. 2010
    ....
  38. ncbi request reprint Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Oncology 65:204-10. 2003
    ..Although hepatocellular carcinoma does develop after sustained response to interferon (IFN) in patients with chronic hepatitis C, details on the clinical prognosis have not been elucidated yet...
  39. ncbi request reprint Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Scand J Gastroenterol 40:688-96. 2005
    ..The long-term effects of multi-course interferon (IFN) monotherapy in patients infected with hepatitis C virus (HCV) are still unclear...
  40. ncbi request reprint Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:341-52. 2006
    ..More substitutions in the rt region and the other proteins may be related to the emergence of severe hepatitis caused by lamivudine-resistant virus...
  41. ncbi request reprint Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine
    Tetsuya Hosaka
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Tokyo 105 8470, Japan
    J Gastroenterol 42:368-74. 2007
    ..The aim of this study was to investigate the factors associated with the response of lamivudine-resistant hepatitis B virus (HBV) during combination therapy with adefovir dipivoxil plus lamivudine...
  42. doi request reprint Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan akuta gi umin ac jp
    Intervirology 53:188-92. 2010
    ..In treatment-resistant patients with genotype 2 chronic hepatitis C the suitable treatment duration is still unclear. The aims were to investigate extending combination therapy with peginterferon plus ribavirin for genotype 2...
  43. doi request reprint Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy
    Yuya Seko
    Department of Hepatology, Toranomon Hospital, Tokyo 105 0001, Japan
    Intervirology 56:13-21. 2013
    ....
  44. ncbi request reprint Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Med Virol 75:550-8. 2005
    ..Further large-scale studies are warranted to examine the role of amino acid substitutions on IFN resistance specific for steatosis...
  45. doi request reprint Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads
    Hitomi Sezaki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 54:1317-24. 2009
    ..Response to treatment in patients with chronic hepatitis C, with reference to age and gender, has not been examined fully...
  46. ncbi request reprint Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment
    Satoshi Mamori
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, 105 8470 Tokyo, Japan
    J Gastroenterol 39:776-82. 2004
    ....
  47. ncbi request reprint Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Med Virol 75:491-8. 2005
    ..None developed cirrhosis or hepatocellular carcinoma (HCC) during follow-up. Our results suggest that long-term lamivudine therapy improves long-term prognosis, especially when additional treatment for breakthrough hepatitis is used...
  48. ncbi request reprint The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Hepatol 38:315-21. 2003
    ..Genotype-dependent development of lamivudine resistance in hepatitis B virus (HBV) has not been reported...
  49. ncbi request reprint Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:1276-83. 2006
    ..36], P = 0.03); it was influenced by genotypes only in patients with HBeAg. In conclusion, HBV genotypes help in predicting response to long-term lamivudine treatment and development of YMDD mutants in patients with chronic hepatitis B...
  50. ncbi request reprint Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients
    Miharu Hirakawa
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:1637-43. 2008
    ..The aim of the present study was to determine the rate of hepatocarcinogenesis and the risk factor in sustained virological responders...
  51. ncbi request reprint Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 46:1827-32. 2007
    ..The aim of this study was to elucidate the side effects after combination therapy of peginterferon and ribavirin for Japanese patients with chronic hepatitis C...
  52. ncbi request reprint Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:1301-7. 2008
    ..The aim of this study was to determine the suitable treatment period in patients who achieve virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C virus infection...
  53. doi request reprint Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo 105 0001, Japan
    Intervirology 52:301-9. 2009
    ....
  54. ncbi request reprint Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 46:182-9. 2003
    ..However, the patient cohorts in such studies are relatively small...
  55. doi request reprint Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 83:1016-22. 2011
    ..This study emphasizes the importance of detection of aa substitutions in the core region before antiviral therapy...
  56. ncbi request reprint Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan
    Yoshiyuki Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 76:33-9. 2005
    ..Infection was cleared in only one of the six (17%) patients who received antiviral therapy...
  57. ncbi request reprint Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 48:174-82. 2005
    ..Comparison of virological and biochemical relapse in patients with chronic hepatitis B, based on continuation or discontinuation of lamivudine monotherapy...
  58. ncbi request reprint The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:355-60. 2008
    ..The aim of this study was to elucidate the efficacy of short-term interferon (IFN) therapy for chronic hepatitis C patients with low virus load...
  59. ncbi request reprint Association of HLA-DR14 with the treatment response in Japanese patients with autoimmune hepatitis
    Yoshiyuki Suzuki
    Department of Hepatology, Toranomon Hospital, Takatsu ku, Kawasaki City, Japan
    Dig Dis Sci 55:2070-6. 2010
    ..Influence of human lymphocyte antigen (HLA) on the therapeutic response in autoimmune hepatitis (AIH) is not known...
  60. ncbi request reprint Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection
    Kiminori Uka
    Department of Gastroenterology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Gastroenterol 41:470-5. 2006
    ..The aim of this study was to analyze the response to interferon (IFN) monotherapy in young HCV patients...
  61. ncbi request reprint Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase
    Kenji Ikeda
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Med 119:977-85. 2006
    ..To elucidate the incidence of hepatitis activation and hepatocellular carcinogenesis in patients with negative HBe antigen and normal aminotransferase, long-term observation was performed in a retrospective cohort...
  62. doi request reprint Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir
    Fumitaka Suzuki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 53:415-21. 2011
    ..039), but the total RBV dose was no different between them (49 ± 17% and 54 ± 18% of the target, P = 0.531). Sustained virological response (SVR) was achieved in 70% and 64% of them, respectively (P = 0.724)...
  63. ncbi request reprint Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, 105 8470, Tokyo, Japan
    J Gastroenterol 39:969-74. 2004
    ..In Japan, there are few studies of long-term (more than 1 month) interferon (IFN) therapy for chronic hepatitis B (CHB). In this retrospective study, we investigated the efficacy and predictors of response to 6-month IFN therapy...
  64. ncbi request reprint Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:60-7. 2006
    ..In conclusion, patients persistently infected with HBV genotype A fare better than those with genotype B or C. However, high levels of HBV DNA continue in those in whom HBeAg persists along with fibrosis in the liver...